Adam J Schoenfeld Selected Research

Ipilimumab

1/2023

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Adam J Schoenfeld Research Topics

Disease

22	Neoplasms (Cancer) 04/2024 - 01/2020
16	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 01/2019
15	Lung Neoplasms (Lung Cancer) 01/2024 - 01/2019
5	Adenocarcinoma of Lung 01/2023 - 01/2019
3	Colitis 03/2024 - 09/2023
2	Ulcerative Colitis 03/2024 - 09/2023
2	Genetic Risk Score 03/2024 - 09/2023
2	Aneuploidy (Aneuploid) 11/2023 - 11/2023
2	Disease Progression 01/2023 - 01/2021
1	Inflammation (Inflammations) 01/2024
1	Dysbiosis 12/2023
1	Turcot syndrome 10/2023
1	Microsatellite Instability 10/2023
1	Cytokine Release Syndrome 01/2023
1	COVID-19 01/2023
1	Pneumonia (Pneumonitis) 01/2023
1	Carcinogenesis 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 03/2021
1	Neoplasm Metastasis (Metastasis) 01/2020
1	Mucinous Adenocarcinoma (Mucinous Carcinoma) 01/2019

Drug/Important Bio-Agent (IBA)

11	Immune Checkpoint InhibitorsIBA 04/2024 - 01/2020
6	osimertinibIBA 01/2023 - 01/2020
5	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2019
4	Biomarkers (Surrogate Marker)IBA 11/2023 - 10/2022
3	durvalumabIBA 11/2023 - 01/2023
3	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2019
2	B7-H1 AntigenIBA 11/2023 - 01/2023
2	dacomitinibIBA 09/2022 - 01/2021
2	lorlatinibIBA 01/2021 - 01/2020
2	entrectinibIBA 01/2021 - 01/2020
2	CrizotinibIBA 01/2021 - 01/2020
2	Bevacizumab (Avastin)FDA Link 12/2020 - 01/2020
1	Interleukin-2 (IL2)IBA 02/2024
1	InterferonsIBA 01/2024
1	PlatinumIBA 11/2023
1	RNA (Ribonucleic Acid)IBA 11/2023
1	Oxygen (Dioxygen)IBA 01/2023
1	IpilimumabIBA 01/2023
1	NivolumabIBA 01/2023
1	Antineoplastic Agents (Antineoplastics)IBA 01/2023
1	pembrolizumabIBA 10/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Transcription Factors (Transcription Factor)IBA 01/2022
1	ChromatinIBA 01/2022
1	Adenosine Triphosphatases (ATPase)IBA 01/2022
1	src-Family KinasesIBA 01/2022
1	Chimeric Antigen ReceptorsIBA 03/2021
1	cabozantinibIBA 01/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020
1	SolventsIBA 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2020
1	repotrectinibIBA 01/2020
1	ceritinibIBA 01/2020
1	cyclo(Arg-Pro) (CI 4)IBA 01/2020
1	Bortezomib (Velcade)FDA Link 01/2019
1	Proteasome InhibitorsIBA 01/2019

Therapy/Procedure

12	Therapeutics 04/2024 - 01/2019
7	Immunotherapy 04/2024 - 11/2020
3	Drug Therapy (Chemotherapy) 11/2023 - 01/2023
2	Cell- and Tissue-Based Therapy (Cell Therapy) 04/2024 - 02/2024
1	Fecal Microbiota Transplantation 12/2023
1	Artificial Respiration (Mechanical Ventilation) 01/2023
1	Precision Medicine 10/2022
1	Complementary Therapies (Alternative Medicine) 01/2021